Therapy Detail

Therapy Name Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin
Synonym Necitumumab + FOLFOX
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Fluorouracil Adrucil 5-FU Chemotherapy - Antimetabolite 10 Adrucil (fluorouracil) is an antimetabolite chemotherapeutic agent, which interferes with DNA and RNA synthesis thereby preventing cancer cell growth (NCI Drug Dictionary). Fluorouracil is FDA approved for colorectal, breast, stomach, and pancreatic cancer (FDA.gov).
Leucovorin Wellcovorin Calcium folinate|Calcium citrovorum factor|folinic acid Chemotherapy - Antimetabolite 10 Wellcovorin (leucovorin) is a metabolite of folate that enhances the efficacy of fluoruracil (NCI Drug Dictionary).
Necitumumab Portrazza IMC-11F8 EGFR Antibody 27 Portrazza (necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).
Oxaliplatin Eloxatin Diaminocyclohexane Oxalatoplatinum Chemotherapy - Platinum 6 Eloxatin (oxaliplatin) is comprised of a platinum complex, which causes DNA-platinum cross-links, inhibition of DNA replication and transcription, and cell toxicity (NCI Drug Dictionary). Eloxatin (oxaliplatin) is FDA approved for colorectal cancer (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS mutant colorectal cancer predicted - sensitive Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin Phase II Actionable In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with an ORR of 56.5% (5/9; all partial responses), and stable disease in 44.4% (4/9) of KRAS-mutant patients (PMID: 26766738). 26766738
KRAS wild-type colorectal cancer predicted - sensitive Fluorouracil + Leucovorin + Necitumumab + Oxaliplatin Phase II Actionable In a Phase II clinical trial, the combination of Portrazza (necitumumab) and FOLFOX in colorectal cancer patients resulted in an objective response rate (ORR) of 63.6% (28/44) in the overall intent-to-treat population, with KRAS wild-type patients achieving an ORR of 87.5% (14/16), including complete response in 25% (4/16), and partial response in 62.5% (10/16) of patients (PMID: 26766738). 26766738
Clinical Trial Phase Therapies Title Recruitment Status